Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Aghazadeh Behzad 2. Date of Event Requiring Statement (Month/Day/Year) 07/23/2026 3. Issuer Name and Ticker or Trading Symbol Scribe Therapeutics, Inc. [SCTX] (Last) (First) (Middle) C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) __X__ Other (specify below) See Remarks 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) NEW YORK, NY 10012 6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock, par value $0.0001 per share 697,650 I See footnotes(1)(2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Aghazadeh Behzad C/O AVORO CAPITAL ADVISORS LLC 110 GREENE STREET, SUITE 800 NEW YORK, NY 10012	X			See Remarks
Avoro Capital Advisors LLC 110 GREENE STREET SUITE 800 NEW YORK, NY 10012	X			See Remarks
Avoro Ventures LLC 110 GREEN STREET, SUITE 800 NEW YORK, NY 10012	X			See Remarks

Signatures

Avoro Capital Advisors LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Compliance Officer		07/23/2026
**Signature of Reporting Person		Date
Avoro Ventures LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Compliance Officer		07/23/2026
**Signature of Reporting Person		Date
/s/ Behzad Aghazadeh		07/23/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The securities reported herein are held on behalf of accounts managed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"). Behzad Aghazadeh ("Dr. Aghazadeh") serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures", and together with Avoro Capital Advisors and Dr. Aghazadeh, the "Reporting Persons").
(2)	The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Remarks: Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the Issuer by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.